1. Home
  2. CAPR vs HIVE Comparison

CAPR vs HIVE Comparison

Compare CAPR & HIVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Capricor Therapeutics Inc.

CAPR

Capricor Therapeutics Inc.

N/A

Current Price

$7.60

Market Cap

584.9M

Sector

Health Care

ML Signal

N/A

Logo HIVE Digital Technologies Ltd.

HIVE

HIVE Digital Technologies Ltd.

N/A

Current Price

$1.15

Market Cap

447.1M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
CAPR
HIVE
Founded
2005
1987
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
584.9M
447.1M
IPO Year
2011
2017

Fundamental Metrics

Financial Performance
Metric
CAPR
HIVE
Price
$7.60
$1.15
Analyst Decision
Buy
Strong Buy
Analyst Count
10
9
Target Price
★ $27.25
$5.17
AVG Volume (30 Days)
4.2M
★ 10.2M
Earning Date
11-10-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
N/A
★ N/A
Revenue
N/A
★ $297,791,000.00
Revenue This Year
N/A
$18.39
Revenue Next Year
$85.77
$41.62
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ 158.32
52 Week Low
$2.96
$1.34
52 Week High
$40.37
$5.34

Technical Indicators

Market Signals
Indicator
CAPR
HIVE
Relative Strength Index (RSI) 48.38 22.34
Support Level $7.78 N/A
Resistance Level $10.62 $2.33
Average True Range (ATR) 1.18 0.13
MACD -0.11 -0.02
Stochastic Oscillator 19.61 1.37

Price Performance

Historical Comparison
CAPR
HIVE

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

About HIVE HIVE Digital Technologies Ltd.

HIVE Digital Technologies Ltd is a sustainable-energy-focused digital infrastructure company that provides infrastructure solutions through the operation of Tier-1 and Tier-3 data centers. Its computing power is used for high-performance computing (HPC) and for generating hashrate sold to mining pools for cryptocurrency mining. The Company uses cash flow from its hashrate services business to support the expansion of its AI and HPC operations through its subsidiary. The Company focuses on Canada, Sweden, and Paraguay, where low-cost renewable power supports its operations and expansion. It operates in one segment with two revenue streams: the mining and sale of digital currencies and high-performance computing hosting. The majority of its revenue is generated from Bermuda.

Share on Social Networks: